ProMIS Neurosciences Inc. (PMN)
NASDAQ: PMN
· Real-Time Price · USD
0.52
-0.04 (-7.96%)
At close: Aug 20, 2025, 3:58 PM
0.51
-3.41%
After-hours: Aug 20, 2025, 07:58 PM EDT
-7.96% (1D)
| Bid | 0.5 |
| Market Cap | 17.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.04M |
| EPS (ttm) | -0.07 |
| PE Ratio (ttm) | -7.5 |
| Forward PE | -0.73 |
| Analyst | Buy |
| Ask | 0.54 |
| Volume | 682,775 |
| Avg. Volume (20D) | 7,100,487 |
| Open | 0.55 |
| Previous Close | 0.56 |
| Day's Range | 0.51 - 0.56 |
| 52-Week Range | 0.38 - 1.59 |
| Beta | -0.03 |
Analyst Forecast
According to 0 analyst ratings, the average rating for PMN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-26.79%
ProMIS Neurosciences shares are trading lower afte...
Unlock content with
Pro Subscription
1 month ago
+154.49%
ProMIS Neurosciences shares are trading higher after the company announced the FDA granted received Fast Track designation to PMN310.
2 years ago · proactiveinvestors.com
ProMIS Neurosciences submits IND application for Alzheimer's treatmentProMIS Neurosciences (TSX:PMN) told investors it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for PMN310 for the treatment of Alzheimer's di...